Teva Pharmaceuticals has confirmed that seasonal hayfever treatment Qnaze has met its target in late-stage clinical trials.

Qnaze was superior to a placebo in improving the morning and evening symptoms, and patients who took the drug had a greater response.

Nasal discomfort, a common side-effect of the medication, occurred at a similar rate to the placebo.

Qnaze is a corticosteroid delivered using an aerosol instead of an aqueous spray.

Teva is also testing the drug as a treatment for perennial allergies occurring throughout the year.